title: Targeting advanced glycation with pharmaceutical agents: where are we now?
abstract: Advanced glycation end products (AGEs) are the final products of the Maillard reaction, a complex process that has been studied by food chemists for a century. Over the past 30 years, the biological significance of advanced glycation has also been discovered. There is mounting evidence that advanced glycation plays a homeostatic role within the body and that food-related Maillard products, intermediates such as reactive α-dicarbonyl compounds and AGEs, may influence this process. It remains to be understood, at what point AGEs and their intermediates become pathogenic and contribute to the pathogenesis of chronic diseases that inflict current society. Diabetes and its complications have been a major focus of AGE biology due to the abundance of excess sugar and α-dicarbonyls in this family of diseases. While further temporal information is required, a number of pharmacological agents that inhibit components of the advanced glycation pathway have already showed promising results in preclinical models. These therapies appear to have a wide range of mechanistic actions to reduce AGE load. Some of these agents including Alagebrium, have translated successfully to clinical trials, while others such as aminoguanidine, have had undesirable side-effect profiles. This review will discuss different pharmacological agents that have been used to reduce AGE burden in preclinical models of disease with a focus on diabetes and its complications, compare outcomes of those therapies that have reached clinical trials, and provide further rationale for the use of inhibitors of the glycation pathway in chronic diseases.
authors.affiliation: Glycation and Diabetes, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Australia.
authors.forename: Danielle J
authors.initials: DJ
authors.lastname: Borg
authors.affiliation: Glycation and Diabetes, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Australia. josephine.forbes@mater.uq.edu.au.|Mater Clinical School, School of Medicine, University of Queensland, St Lucia, Australia. josephine.forbes@mater.uq.edu.au.|Department of Medicine, The University of Melbourne, Austin Hospital, Heidelberg, Australia. josephine.forbes@mater.uq.edu.au.|Baker IDI Heart and Diabetes Institute, Melbourne, Australia. josephine.forbes@mater.uq.edu.au.
authors.forename: Josephine M
authors.initials: JM
authors.lastname: Forbes
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D015416:Maillard Reaction / Q000187:drug effects*; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D017127:Glycation End Products, Advanced; D013844:Thiazoles; C406794:alagebrium
keywords: Advanced glycation end products; Advanced glycation pathway; Alagebrium; Aminoguanidine; Diabetes; Diabetes complications; Maillard reaction; Methylglyoxal; Pyridoxamine